Professorial Nominations to Katarzyna Łukasiuk, Wiesława Leśniak and Anna Nowicka

On April 26, 2018, celebration was held at the Nencki Institute for Prof. Katarzyna Łukasiuk, Prof. Wiesława Leśniak and Prof. Anna Nowicka, who received Professorial Nominations signed by the President of Poland, Andrzej Duda.

Prof. Katarzyna Łukasiuk is a head of the Laboratory of Epileptogenesis. Research of her group is concentrated on the molecular responses to brain injury, molecular events leading to the development of epilepsy and biomarkers of epileptogenesis and epilepsy. Prof. Łukasiuk is also interested in developing new strategies to prevent epilepsy development and in development of new in vivo models of epilepsy. Prof. Łukasiuk is a secretary of the Scientific Council of the Nencki Institute, secretary of the Neurobiology Committee of the Polish Academy of Sciences, member of the Board of Referees of Acta Neurobiologiae Experimentalis and consulting editor of Epilepsy Research.

Prof. Wiesława Leśniak started her scientific work in the field of biological membranes and membrane proteins, mostly those involved in active ion transport across membranes (ATPases). At present, her studies concentrate on the S100A6 protein, which belongs to a specific group of calcium binding proteins, and cover a wide range of issues such as interactions of S100A6 with other proteins or its involvement in cell growth, differentiation, senescence and other cellular processes. Her scientifc interests extend to the field of gene expression and epigenetics with the focus on the S100A6 gene (and other genes) expression regulation. 

Earlier studies of prof. Anna Nowicka were focused on the perception of visual illusion, communication of the two hemispheres of the human brain, and mechanisms of memory processes (including the phenomenon of intentional forgetting). Recently, using electrophysiological and functional magnetic resonance imaging approaches, prof. Nowicka is investigating neurobiological basis of self-related information processing in general population and in individuals with autism spectrum disorder. 

Date of publication
4 May 2018